hengrui glp 1 Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 | Tue, 07/15/2025 Hengrui Pharma's GLP-1R Agonist Patent

A novel ASCT2 inhibitor, C118P, blocks glutamine transport and exhibits antitumour efficacy in breast cancer

Search online, and you may find theres at least one in your city or town

Because NAD plays a central role in energy production and metabolic regulation, this compound is commonly used in studies focused on metabolism, cell signaling, and molecular resilience

Correct safe medication mixing supports patient safety outcomes

Notably, patients with variants in the linker, MTS, or P domains exhibited later onset, milder epilepsy severity, and better responsiveness to antiepileptic drugs, suggesting that the functional domain distribution of LONP1 variants may influence the severity grading of epileptic phenotypes [89]